Copd
Reading File
Finding Sources
Searching PubMed
"chronic obstructive pulmonary disease"[MeSH Terms] AND "management"[MeSH Terms]
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Here is a thorough overview of COPD based on authoritative medical textbook sources:
Chronic Obstructive Pulmonary Disease (COPD)
Definition
COPD is a progressive disorder characterized by persistent, largely irreversible airflow limitation caused by an abnormal inflammatory response of the lung to noxious particles or gases - most commonly cigarette smoke. It encompasses two overlapping clinical entities:
- Emphysema - destruction of alveolar walls with loss of elastic recoil
- Chronic bronchitis - persistent productive cough for at least 3 consecutive months in at least 2 consecutive years
(Robbins & Kumar Basic Pathology; Katzung's Basic and Clinical Pharmacology, 16e)
Epidemiology
- Third most common cause of death in the United States
- Accounts for over $40 billion/year in direct and indirect healthcare costs
- Smoking causes COPD in approximately 15-30% of habitual smokers by traditional estimates, though radiographic studies show important progressive changes in bronchial wall thickness and lung tissue even in smokers with normal spirometry
- (Katzung's Basic and Clinical Pharmacology, 16e)
Risk Factors
| Risk Factor | Notes |
|---|---|
| Cigarette smoking | Primary cause (pack-years strongly correlated) |
| α1-antitrypsin deficiency | Causes panacinar emphysema |
| Air pollution / occupational dusts | Contributing factor |
| Recurrent respiratory infections | Exacerbate progression |
Pathophysiology
Emphysema
- Enlargement of air spaces distal to terminal bronchioles due to destruction of elastic support structures
- Proteases (mainly from neutrophils) degrade alveolar walls
- Two subtypes:
- Centriacinar (most common) - smoking-related, upper lobe predominance
- Panacinar - seen in α1-antitrypsin deficiency, lower lobe predominance
- Results in: increased chest volume (barrel chest), dyspnea, relatively preserved blood O2 at rest ("pink puffer" phenotype)
Chronic Bronchitis
- Mucus hypersecretion from hyperplasia of tracheal and large airway mucous glands
- Airway obstruction driven by small airway inflammation (chronic bronchiolitis)
- Histology: enlarged mucus-secreting glands, goblet cell metaplasia, bronchiolar wall fibrosis
- Results in: hypoxemia and hypercapnia ("blue bloater" phenotype)
(Robbins & Kumar Basic Pathology)
Hypercapnia in Advanced COPD
- PaCO2 usually does not rise until FEV1 falls to ~20-25% of predicted
- Caused by: increased dead-space ventilation, V/Q mismatch, diaphragmatic dysfunction, impaired chemoreceptor response
- Dynamic hyperinflation worsens with disease progression - the diaphragm flattens, reducing its mechanical efficiency
- Persistent hypercapnia is a poor prognostic indicator and correlates with shorter survival
(Fishman's Pulmonary Diseases and Disorders)
Gas Exchange
- Classic ABG in moderate-severe COPD: low PaO2 (~60 mmHg), normal or elevated PaCO2, compensatory pH changes
- A-a gradient is widened, confirming V/Q mismatch rather than pure hypoventilation
- (Costanzo Physiology 7e)
Diagnosis
| Test | Finding in COPD |
|---|---|
| Spirometry (post-bronchodilator) | FEV1/FVC < 0.70 (confirms obstruction) |
| FEV1 | Reduced (determines severity per GOLD) |
| FVC | Normal or near-normal |
| Chest X-ray | Hyperinflation, flattened diaphragm, barrel chest |
| ABG | Low PaO2, elevated/normal PaCO2 |
| Alpha-1 antitrypsin level | If early-onset or non-smoker |
GOLD Severity Classification (by FEV1 % predicted post-bronchodilator):
| Stage | FEV1 % predicted |
|---|---|
| GOLD 1 (Mild) | ≥ 80% |
| GOLD 2 (Moderate) | 50-79% |
| GOLD 3 (Severe) | 30-49% |
| GOLD 4 (Very Severe) | < 30% |
COPD vs. Asthma
| Feature | COPD | Asthma |
|---|---|---|
| Age at onset | Older patients (> 40 yrs) | Often childhood/young adult |
| Smoking history | Strongly associated | Variable |
| Inflammation type | Neutrophilic | Eosinophilic |
| Response to ICS | Poor (except high eosinophils) | Excellent |
| Reversibility | Largely irreversible | Largely reversible |
| Progression | Relentless (with smoking) | Not typically progressive |
(Katzung's Basic and Clinical Pharmacology, 16e)
Treatment
Non-Pharmacologic
- Smoking cessation - most important intervention; slows disease progression
- Pulmonary rehabilitation - improves dyspnea and exercise tolerance
- Long-term oxygen therapy (LTOT) - for resting PaO2 ≤ 55 mmHg (or ≤ 60 with cor pulmonale/polycythemia); only treatment proven to improve survival in hypoxemic COPD
Pharmacologic (Stepwise)
Stable COPD:
| Severity | Treatment |
|---|---|
| Mild (GOLD 1-2, few symptoms) | SABA (albuterol) as needed |
| Moderate-Severe (persistent dyspnea) | LABA or LAMA (long-acting anticholinergic) as regular therapy; combination LABA + LAMA for greater benefit |
| Severe with frequent exacerbations | Add ICS (if high eosinophils or asthma overlap); consider roflumilast |
| Recurrent exacerbations | Prophylactic azithromycin (daily) shown to reduce exacerbation frequency |
Key drug classes:
- SABAs: Albuterol (salbutamol) - rapid relief of acute bronchospasm
- LABAs: Salmeterol, formoterol, vilanterol - 12-24h duration, preventive
- SAMAs: Ipratropium - short-acting muscarinic antagonist
- LAMAs: Tiotropium, umeclidinium - once-daily, preferred for COPD
- ICS: Fluticasone, budesonide - for severe COPD or high eosinophil count; increases pneumonia risk
- Roflumilast: Selective PDE4 inhibitor - improves lung function and reduces exacerbations
- Theophylline: Largely fallen out of favor; a large RCT showed no benefit on exacerbation frequency
Acute Exacerbations
- Triggered most often by viral or bacterial respiratory infections
- Management: increased bronchodilators (SABA + ipratropium), systemic corticosteroids (5-7 days), antibiotics (routinely used because bacterial infection is common - β-lactams, doxycycline, azithromycin targeting S. pneumoniae and H. influenzae)
- ICU/NIV (non-invasive ventilation) for respiratory failure
(Katzung's Basic and Clinical Pharmacology, 16e; Fishman's Pulmonary Diseases and Disorders)
Complications
| Complication | Details |
|---|---|
| Cor pulmonale | Right heart failure from chronic pulmonary hypertension |
| Polycythemia | Secondary to chronic hypoxia |
| Respiratory failure | Hypoxemic and/or hypercapnic |
| Lung cancer | Shared risk factor (smoking) |
| Pneumothorax | Ruptured bullae |
| Recurrent pneumonias | Impaired mucociliary clearance |
Key Comparison: "Pink Puffer" vs "Blue Bloater"
| Emphysema ("Pink Puffer") | Chronic Bronchitis ("Blue Bloater") | |
|---|---|---|
| Build | Thin, cachectic | Overweight |
| Breathlessness | Severe at rest | Moderate |
| Cough | Minimal | Prominent, productive |
| Cyanosis | Absent/mild | Prominent |
| PaO2 | Relatively maintained | Significantly reduced |
| PaCO2 | Normal or low | Elevated |
| Cor pulmonale | Late | Earlier |
Sources:
- Robbins & Kumar Basic Pathology
- Katzung's Basic and Clinical Pharmacology, 16th Edition
- Fishman's Pulmonary Diseases and Disorders
- Costanzo Physiology, 7th Edition
- Berek & Novak's Gynecology (perioperative COPD management)
This is a shared conversation. Sign in to Orris to start your own chat.